UC UC UC UC UC UC UC UC UC UC UC .../ DE000HB993B5 /
2024-05-31 11:45:21 AM | Chg.-0.0500 | Bid1:37:15 PM | Ask1:37:15 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.7700EUR | -2.75% | 1.8400 Bid Size: 100,000 |
1.8500 Ask Size: 100,000 |
SANOFI SA INHABER ... | 70.3732 EUR | 2078-12-31 | Call |
GlobeNewswire
7:05 AM
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
7:05 AM
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
7:00 AM
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
7:00 AM
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
05-30
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
05-27
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
05-21
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...